Celgene says Phase 3 Otezla study meets primary, secondary endpoints

Celgene Corporation announced results from the phase 3 STYLE study, which showed that Otezla 30 mg twice daily achieved a highly statistically significant improvement in the primary endpoint of the Scalp Physician’s Global Assessment response [defined as ScPGA score of clear or almost clear with at least a 2-point reduction from baseline] at week 16 compared with placebo. In addition to achieving the primary endpoint, statistical significance was also met for the secondary endpoint of the whole body itch numeric rating scale at week 16 with Otezla versus placebo. The safety profile was generally consistent with the known safety profile of Otezla, and no new safety signals were identified in the trial.
https://thefly.com/landingPageNews.php?id=2801229